lenalidomid teva b.v. 25 mg
teva b.v., holandsko - lenalidomid - 59 - immunopraeparata
lenalidomid zentiva 25 mg tvrdé kapsuly
zentiva k.s., Česká republika - lenalidomid - 59 - immunopraeparata
lenalidomid zentiva 15 mg tvrdé kapsuly
zentiva k.s., Česká republika - lenalidomid - 59 - immunopraeparata
lenalidomid zentiva 10 mg tvrdé kapsuly
zentiva k.s., Česká republika - lenalidomid - 59 - immunopraeparata
lenalidomid glenmark 25 mg
glenmark pharmaceuticals s.r.o., Česká republika - lenalidomid - 59 - immunopraeparata
lenalidomid glenmark 15 mg
glenmark pharmaceuticals s.r.o., Česká republika - lenalidomid - 59 - immunopraeparata
lenalidomid glenmark 10 mg
glenmark pharmaceuticals s.r.o., Česká republika - lenalidomid - 59 - immunopraeparata
lenalidomid glenmark 5 mg
glenmark pharmaceuticals s.r.o., Česká republika - lenalidomid - 59 - immunopraeparata
sarclisa
sanofi winthrop industrie - isatuximab - viacnásobný myelóm - antineoplastické činidlá - sarclisa is indicated: in combination with pomalidomide and dexamethasone, for the treatment of adult patients with relapsed and refractory multiple myeloma (mm) who have received at least two prior therapies including lenalidomide and a proteasome inhibitor (pi) and have demonstrated disease progression on the last therapy. in combination with carfilzomib and dexamethasone, for the treatment of adult patients with multiple myeloma who have received at least one prior therapy (see section 5.
lenalidomide mylan
mylan ireland limited - lenalidomid - viacnásobný myelóm - imunosupresíva - multiple myelomalenalidomide mylan as monotherapy is indicated for the maintenance treatment of adult patients with newly diagnosed multiple myeloma who have undergone autologous stem cell transplantation. lenalidomide mylan as combination therapy with dexamethasone, or bortezomib and dexamethasone, or melphalan and prednisone is indicated for the treatment of adult patients with previously untreated multiple myeloma who are not eligible for transplant. lenalidomide mylan in combination with dexamethasone is indicated for the treatment of multiple myeloma in adult patients who have received at least one prior therapy. follicular lymphomalenalidomide mylan in combination with rituximab (anti-cd20 antibody) is indicated for the treatment of adult patients with previously treated follicular lymphoma (grade 1-3a).